The importance of early-phase clinical trials in developing new cancer therapies.

Clifton Rooney*

Department of Internal Medicine, Chang Gung University, Taiwan

Introduction

Cancer remains one of the leading causes of death worldwide, and despite significant progress in cancer treatment, many cancers are still difficult to treat effectively. The development of new cancer therapies is critical for improving patient outcomes, and clinical trials play a pivotal role in this process. Early-phase clinical trials, in particular, are vital for laying the foundation of new treatments, providing essential insights into the safety, efficacy, and potential benefits of emerging therapies. This article explores the importance of early-phase clinical trials in the development of new cancer therapies [1].

Early-phase clinical trials, typically referred to as Phase I and Phase II studies, are the first stages of human testing for new drugs or treatments. Phase I trials focus primarily on assessing the safety of a new treatment, determining the correct dosage, and identifying potential side effects. Phase II trials begin to evaluate the effectiveness of the treatment, while still closely monitoring safety and tolerability. These trials are essential for moving promising therapies from the laboratory to real-world clinical application [2].

In early-phase trials, researchers test new therapies on small groups of patients, often those with advanced or treatment-resistant cancers. These patients have typically exhausted other treatment options, making them ideal candidates to test experimental drugs. While the primary goal is to assess safety, these trials also provide valuable data that help to refine the treatment and inform the design of later-stage trials [3].

One of the most important contributions of early-phase trials is their ability to identify promising new therapies that can eventually lead to life-saving treatments. Many of today's standard cancer treatments, such as targeted therapies and immunotherapies, began as experimental treatments in early-phase clinical trials. For example, the breakthrough drug imatinib (Gleevec), which revolutionized the treatment of chronic myelogenous leukemia (CML), was tested and refined through Phase I and II trials before becoming a widely used therapy [4].

Without early-phase trials, many of these breakthrough treatments would not have advanced to later stages of development. These trials act as the first step in translating laboratory discoveries into real-world solutions. If a new treatment demonstrates promising results in early trials, it is then eligible for larger Phase III trials, which are designed to confirm its efficacy and safety in a broader population [5].

One of the primary reasons early-phase clinical trials are essential is their focus on safety. New therapies are often tested in patients who have no other treatment options, meaning that any potential side effects or toxicities must be carefully monitored. Phase I trials focus on identifying the maximum tolerated dose (MTD) and understanding the adverse reactions that patients may experience. This step is crucial in preventing serious side effects that could endanger patients and limit the drug's potential in future use [6].

By systematically increasing doses and monitoring patients closely, researchers can also determine the optimal dose of a new treatment that balances efficacy with safety. This process is vital for determining whether a new therapy can be used in larger populations and for treating different types of cancers [7].

Early-phase clinical trials are not limited to testing traditional chemotherapy or radiation therapies. Over the past two decades, the landscape of cancer treatment has been dramatically transformed by the advent of targeted therapies and immunotherapies. These therapies are designed to target cancer cells more specifically, reducing the damage to healthy cells and potentially resulting in fewer side effects [8].

In early-phase trials, researchers test these new approaches, including monoclonal antibodies, checkpoint inhibitors, and CAR-T cell therapies. For instance, the successful clinical testing of immune checkpoint inhibitors like nivolumab (Opdivo) and pembrolizumab (Keytruda) began in early-phase trials, where they showed promise in treating cancers like melanoma and non-small cell lung cancer. Today, these drugs are now standard treatments for a variety of cancers, demonstrating the power of early-phase trials in identifying revolutionary therapies [9].

Personalized cancer treatment, also known as precision medicine, has become an increasingly important focus in oncology. Early-phase clinical trials play a crucial role in advancing personalized treatment approaches by allowing researchers to test therapies based on a patient's unique genetic makeup. By using genetic and molecular profiling, researchers can identify specific mutations and alterations in cancer cells, enabling them to design drugs that target these abnormalities [10].

***Correspondence to:** Clifton Rooney, Department of Internal Medicine, Chang Gung University, Taiwan. E-mail: clifton.rooney@yahoo.com.tw

***Received:** 1-May-2025, Manuscript No. JMOT-25-164952; **Editor assigned:** 5-May-2025, PreQC No. JMOT-25-164952 (PQ); **Reviewed:** 19-May-2025, QC No. JMOT-25-164952; **Revised:** 26-May-2025, Manuscript No. JMOT-25-164952 (R); **Published:** 31-May-2025, DOI: 10.35841/jmot-10.3.262*

***Citation:** Rooney C. The importance of early-phase clinical trials in developing new cancer therapies. J Med Oncl Ther. 2025;10(3):262.*

Conclusion

Early-phase clinical trials are the bedrock upon which the development of new cancer therapies is built. They provide the critical data needed to move experimental treatments into larger trials, and ultimately, into clinical practice. By assessing safety, determining optimal doses, exploring new therapeutic approaches, and overcoming drug resistance, these trials play an indispensable role in improving cancer care. As cancer research continues to evolve, the importance of early-phase clinical trials will only grow, offering hope for the next generation of cancer therapies that will save countless lives in the future.

References

1. Harrington JA, Hernandez-Guerrero TC, Basu B. Early phase clinical trial designs–state of play and adapting for the future. Clin Oncol. 2017;29(12):770-7.
2. Bui NQ, Kummar S. Evolution of early phase clinical trials in oncology. J Mol Med. 2018;96(1):31-8.
3. Mansinho A, Boni V, Miguel M, et al. New designs in early clinical drug development. Ann Oncol. 2019;30(9):1460-5.
4. Tan DS, Thomas GV, Garrett MD, et al. Biomarker-driven early clinical trials in oncology: A paradigm shift in drug development. Cancer J. 2009;15(5):406-20.
5. Kinders R, Parchment RE, Ji J, et al. Phase 0 clinical trials in cancer drug development: From FDA guidance to clinical practice. Mol Interv. 2007;7(6):325.
6. Murgo AJ, Kummar S, Rubinstein L, et al. Designing phase 0 cancer clinical trials. Clin Cancer Res. 2008;14(12):3675-82.
7. Nicolò E, Gandini S, Giugliano F, et al. Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials. Eur J Cancer. 2024;207:114181.
8. Cook N, Hansen AR, Siu LL, et al. Early phase clinical trials to identify optimal dosing and safety. Mol Oncol. 2015;9(5):997-1007.
9. Rossi A, Pilotto S, Carbognin L, et al. Modern challenges for early-phase clinical trial design and biomarker discovery in metastatic non-small-cell lung cancer. J Mol Pathol. 2021;2(3):207-22.
10. Collins JM, Grieshaber CK, Chabner BA. Pharmacologically guided phase I clinical trials based upon preclinical drug development. J Natl Cancer Inst. 1990;82(16):1321-6.

Citation: *Rooney C. The importance of early-phase clinical trials in developing new cancer therapies. J Med Oncl Ther. 2025;10(3):262.*